Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome

  title={Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome},
  author={James J. Crowley and Robert Lipsky and Irwin Lucki and Wade H. Berrettini},
  journal={Psychiatric Genetics},
The identification of genetic variants regulating antidepressant response would allow for more individualized, rational, and successful drug treatments. We previously identified a region of mouse chromosome 19 that strongly influences citalopram response in an antidepressant model, the tail suspension test. By virtue of their location in this loci, expression in brain, and involvement in monoamine neurotransmission, we nominated SLC18A2 (encoding vesicular monoamine transporter 2, a.k.a. VMAT2… Expand
Association Study of the Beta-Adrenergic Receptor Genetic Variant Gly389Arg and Fluoxetine Response in Major Depression
The study indicated no significant relationship between β1AR polymorphism and the patient’s response to fluoxetine neither at genotypic nor allelic level, and did not support the hypothesis of involvement ofβ1AR Arg389Gly polymorphisms and response to influenza in MDD patients. Expand
Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease
Evidence is added to the previous evidence suggesting that variability in VMAT2 promoter region may confer a reduced risk of developing PD, presumably via mechanisms of gene overexpression. Expand
Pharmacogenetics of Antidepressants
In conclusion, gene variants seem to influence human behavior, liability to disorders and treatment response, and gene × environment interactions have been hypothesized to modulate several of these effects. Expand
Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.
This chapter describes the basic concepts in PGx of AD response, reviews the major pharmacokinetic and pharmacodynamic genes involved in AD outcome, discusses PRS as a promising approach for predicting AD efficacy and tolerability, and addresses key challenges to the development and application of PGx tests. Expand
Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research
  • C. Fabbri, G. di Girolamo, A. Serretti
  • Medicine
  • American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • 2013
The present review collected the main pharmacogenetic findings primarily about antidepressant response and secondly about antidepressant induced side effects, and discussed the main strengths and limits of both candidate and genome‐wide association studies and the most promising methodological opportunities and challenges of the field. Expand
Revisiting the behavioral genetics of serotonin: relevance to anxiety and depression
The behavioral consequences of manipulation of genes that regulate serotonergic signaling in rodents are described and analogous genetic association studies in humans that relate to psychiatric disorders are reviewed, with a focus on depression and anxiety disorders. Expand
Drugs, genes and the blues: Pharmacogenetics of the antidepressant response from mouse to man
Data from both clinical and preclinical studies that point to a role of specific genes in the response and resistance to antidepressant therapeutics are summarized and how such findings have increased understanding of the mechanism of action of antidepressant drugs are discussed. Expand
Pharmacogenetics of Antidepressant Drugs: An Update
The major findings related to the pharmacogenetics of genes involved in the pharmacokinetics and pharmacodynamics of antidepressant drugs are critically reviewed. Expand
Molecular network-selected pharmacogenomics in a case of bipolar spectrum disorder.
Results from the pharmacogenomic analysis indicate mutations associated with low monoaminergic tone, but also a hyperactive 5HT2A receptor, a feature that associates to a high probability of developing a bipolar condition, especially under 5-hydroxytryptamine potentiating pharmacology. Expand
Blood-based biomarkers predicting response to antidepressants
There is still a great need for studies investigating and validating biomarkers for the prediction of treatment response to facilitate the treatment selection and shorten the time to remission and thus provide personalized medicine in psychiatry. Expand


Analysis of Association Between the Serotonin Transporter and Antidepressant Response in a Large Clinical Sample
The lack of association between response to an SSRI and variation at the SLC6A4 locus in this large sample, carefully characterized for response to citalopram, strongly suggests that SSRI response in major depression is not determined by DNA variation at this locus. Expand
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.
There is a compelling case for a key role of HTR2A in the mechanism of antidepressant action, as detected in patients treated with the antidepressant citalopram. Expand
Pharmacogenomic Evaluation of the Antidepressant Citalopram in the Mouse Tail Suspension Test
The present quantitative trait study suggests possible candidate genes for human pharmacogenetic studies of therapeutic responses to SSRIs such as citalopram, and three candidate genes residing in this locus include those for vesicular monoamine transporter 2 (VMAT2, slc18a2), alpha 2A adrenergic receptor (adra2a), and beta 1 adrenergic receptors (adrb1). Expand
The functional significance of genetic variation within the beta-adrenoceptor.
The data on the in vitro behaviour of these two receptor variants is reviewed here, along with the evidence that they may affect both the risk of cardiovascular disease and the therapeutic response to beta-1 adrenoceptor antagonists. Expand
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.
It is demonstrated that, although common variation tends to be shared between populations, tagSNPs should be selected separately for populations with different ancestries. Expand
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials. Expand
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
The primary outcome is the clinician-rated, 17-item Hamilton Rating Scale for Depression, administered at entry and exit from each treatment level through telephone interviews by assessors masked to treatment assignments. Expand
STAR*D Study Team
  • Am J Psychiatry
  • 2006